
|Articles|August 1, 2001
- Pharmaceutical Executive-08-01-2001
- Volume 0
- Issue 0
Science-Driven Marketing
Author(s)Wayne Koberstein
That marketing should begin early in product development has become a truism in the pharma industry. But as a statement on its own, it sheds little light. What does it mean to begin? At what point do marketers insert themselves into the process? To what end do they enter where once only scientists trod? And, the ultimate question—which the truism fails to answer—how might their intrusion affect the lives of patients, in trial or thereafter?
Advertisement
Articles in this issue
almost 25 years ago
Decision Making at Digital Speedalmost 25 years ago
Mergers: Big Pharma Shrinks Somealmost 25 years ago
Generics: Streamline and Stimulatealmost 25 years ago
Grace Under Firealmost 25 years ago
Get Ready to Merge or Divergealmost 25 years ago
Pharma's Quantum ShuffleAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5




